compounded tirzepatide

The Battle for Compounded GLP-1 Access: Regulatory Pressure, Litigation, and Affordability Executive Summary As of January 2026, the market for compounded GLP-1 receptor agonists—specifically semaglutide and tirzepatide—is at a volatile crossroads. Originally serving as a critical alternative...

Everyone is talking about GLP-1s. As these so-called "miracle drugs" for weight loss exploded in popularity, shortages quickly followed. That’s when compounding pharmacies stepped in, offering lower-cost, customizable versions of these medications. But are patients really getting the same...

The FDA’s recent regulatory crackdown on tirzepatide compounding has far-reaching implications for both pharmacies and patients. Strict deadlines have been set for compounding pharmacies to stop producing tirzepatide, leaving many individuals concerned about affordable access and treatment...